Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Inclusion Criteria

• •1. Adults aged 18 to 80
• •2. History of keloid scar for at least 12 months
• •3. Absence of keloid treatment for past 12 months
• •4. Participant must have a keloid scar of at least 4cm in length.
• •5. Participants who score at least 8 or higher on the Vancouver Scar Scale
• •6. Subjects who score 5 (neither satisfied nor dissatisfied) to 10 (maximally dissatisfied) on the patient subjective score of dissatisfaction with keloid.
• •7. Participants must be in stable health, as confirmed by medical history, per investigator judgment
• •8. Participants must be able to read, sign, and understand the informed consent
• •9. Participants must be willing to avoid any other treatments to the keloid that will be treated including corticosteroid injections, surgical excision, chemotherapeutic injection, lasers, light-based therapy, radiation therapy, cryotherapy, or pressure therapy, during the study period.